Correction to: An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy

Affiliations

• ¹ School of Medicine, University of Notre Dame Australia, Sydney, NSW, Australia.
• ² Department of Clinical Microbiology, SydPath, St Vincent's Hospital, Sydney, NSW, Australia.
• ³ Department of Intensive Care Medicine, St Vincent's Hospital, Sydney, NSW, Australia.
• ⁴ St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
• ⁵ Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, NSW, Australia.
• ⁶ School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, SA, Australia.
• ⁷ Department of Chemical Pathology, SydPath, St Vincent's Hospital, Sydney, NSW, Australia.
• ⁸ Discipline of Clinical Pharmacology, School of Medicine & Public Health, University of Newcastle, Newcastle, NSW, Australia.
• ⁹ Hunter Medical Research Institute, Kookaburra Circuit, New Lambton Heights, NSW, Australia.
• ¹⁰ Department of Clinical Microbiology, SydPath, St Vincent's Hospital, Sydney, NSW, Australia. Indy.Sandaradura@health.nsw.gov.au.
• ¹¹ St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. Indy.Sandaradura@health.nsw.gov.au.
• ¹² Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, NSW, Australia. Indy.Sandaradura@health.nsw.gov.au.